5-Year Data for Vyxeos Liposomal: Perspectives From the United Kingdom (UK)

Back to resources

Watch as physicians from leading UK haematology centres share their thoughts on the 5-year results of Vyxeos Liposomal in Study 301, presented at the European Hematology Association (EHA) Virtual Congress 2020.1

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data

FOOTNOTES

EHA, the European Hematology Association; UK, United Kingdom.

REFERENCES:
  1. Lancet JE, et al. E-poster EP556. EHA25 Virtual Congress 2020

ADVERSE EVENTS REPORTING

Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2000171 | March 2021